The UK startup is seeking to leverage a biobank of serum samples collected as part of a 15-year longitudinal ovarian cancer screening trial in order to forge partnerships for diagnostic test development.
Under the terms of an agreement, Protagen's UNIarray platform will be used to retrospectively analyze samples from a Biogen clinical trial in order to find predictive and response biomarkers in relapsing remitting MS.
Epistem is currently beta-testing a point-of care molecular diagnostic platform called Genedrive that will be able to deliver test results in under 30 minutes. The company sees the platform as a natural translation path for its biomarker discovery business.
OncoTrack, a new international consortium, will seek to generate high-quality genomic and epigenetic data from clinically well-defined colon cancer tumors and their metastases as part of its colon cancer project.